Name | Number of supported studies | Average coverage | |
---|---|---|---|
plasmacytoid dendritic cell | 5 studies | 18% ± 2% | |
B cell | 4 studies | 23% ± 4% | |
retinal rod cell | 4 studies | 18% ± 2% | |
epithelial cell | 3 studies | 23% ± 2% | |
retinal cone cell | 3 studies | 25% ± 4% |
Insufficient scRNA-seq data for expression of MARCHF9 at tissue level.
Tissue | GTEx Coverage | GTEx Average TPM | GTEx Number of samples | TCGA Coverage | TCGA Average TPM | TCGA Number of samples |
---|---|---|---|---|---|---|
esophagus | 100% | 1086.26 | 1445 / 1445 | 100% | 18.65 | 183 / 183 |
pancreas | 100% | 911.68 | 328 / 328 | 100% | 21.89 | 178 / 178 |
thymus | 100% | 2472.67 | 653 / 653 | 100% | 28.15 | 605 / 605 |
lung | 100% | 1704.72 | 578 / 578 | 100% | 25.26 | 1154 / 1155 |
brain | 100% | 1534.92 | 2633 / 2642 | 100% | 61.61 | 705 / 705 |
intestine | 100% | 1318.05 | 966 / 966 | 100% | 20.26 | 525 / 527 |
kidney | 100% | 2248.74 | 89 / 89 | 99% | 27.24 | 896 / 901 |
prostate | 100% | 1544.16 | 245 / 245 | 99% | 20.64 | 499 / 502 |
stomach | 100% | 1054.31 | 359 / 359 | 99% | 18.25 | 284 / 286 |
adrenal gland | 100% | 1553.67 | 258 / 258 | 99% | 30.45 | 228 / 230 |
ovary | 99% | 776.82 | 178 / 180 | 100% | 22.59 | 430 / 430 |
bladder | 100% | 899.29 | 21 / 21 | 99% | 20.27 | 497 / 504 |
uterus | 99% | 807.18 | 168 / 170 | 100% | 19.57 | 457 / 459 |
breast | 100% | 956.54 | 459 / 459 | 98% | 18.29 | 1098 / 1118 |
skin | 85% | 1051.03 | 1543 / 1809 | 98% | 18.34 | 461 / 472 |
liver | 90% | 384.66 | 203 / 226 | 63% | 6.70 | 255 / 406 |
lymph node | 0% | 0 | 0 / 0 | 100% | 35.94 | 29 / 29 |
spleen | 100% | 2496.70 | 241 / 241 | 0% | 0 | 0 / 0 |
tonsil | 0% | 0 | 0 / 0 | 100% | 17.59 | 45 / 45 |
ureter | 0% | 0 | 0 / 0 | 100% | 25.07 | 1 / 1 |
adipose | 100% | 805.99 | 1199 / 1204 | 0% | 0 | 0 / 0 |
blood vessel | 99% | 947.65 | 1325 / 1335 | 0% | 0 | 0 / 0 |
heart | 99% | 962.99 | 852 / 861 | 0% | 0 | 0 / 0 |
muscle | 99% | 697.58 | 791 / 803 | 0% | 0 | 0 / 0 |
peripheral blood | 92% | 969.58 | 852 / 929 | 0% | 0 | 0 / 0 |
eye | 0% | 0 | 0 / 0 | 88% | 8.42 | 70 / 80 |
abdomen | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
bone marrow | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
diaphragm | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
gingiva | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
nasal cavity | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
nasopharynx | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
nose | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
placenta | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
spinal column | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
GO_0016567 | Biological process | protein ubiquitination |
GO_0005802 | Cellular component | trans-Golgi network |
GO_0005795 | Cellular component | Golgi stack |
GO_0000139 | Cellular component | Golgi membrane |
GO_0005765 | Cellular component | lysosomal membrane |
GO_0004842 | Molecular function | ubiquitin-protein transferase activity |
GO_0008270 | Molecular function | zinc ion binding |
Gene name | MARCHF9 |
Protein name | E3 ubiquitin-protein ligase MARCHF9 (EC 2.3.2.27) (Membrane-associated RING finger protein 9) (Membrane-associated RING-CH protein IX) (MARCH-IX) (RING finger protein 179) (RING-type E3 ubiquitin transferase MARCHF9) |
Synonyms | MARCH9 RNF179 |
Description | FUNCTION: E3 ubiquitin-protein ligase that may mediate ubiquitination of MHC-I, CD4 and ICAM1, and promote their subsequent endocytosis and sorting to lysosomes via multivesicular bodies. E3 ubiquitin ligases accept ubiquitin from an E2 ubiquitin-conjugating enzyme in the form of a thioester and then directly transfer the ubiquitin to targeted substrates. . |
Accessions | ENST00000266643.6 [Q86YJ5-1] Q86YJ5 ENST00000548358.1 [Q86YJ5-2] |